Shanghai Pharma Collaborates with Novartis China on Ophthalmic Products
China’s Shanghai Pharmaceuticals Holding Ltd (SPH, HKG: 2607, SHA: 601607) announced this week a strategic...
Novartis
Novartis’ Scemblix Approved by NMPA for Newly Diagnosed Ph+ CML-CP Patients
Swiss pharmaceutical company Novartis (NYSE: NVS) announced that it has received marketing approval from China’s...
Novartis’ Kisqali Receives NMPA Approval for High-Risk Early Breast Cancer
Switzerland-based Novartis (NYSE: NVS) announced this week that it has received another indication approval from...
Novartis to Acquire Regulus Therapeutics for Up to $1.7 Billion
Swiss pharmaceutical giant Novartis (NYSE: NVS) is set to acquire U.S.-based Regulus Therapeutics Inc. (NASDAQ:...
Novartis Q1 2025 Results: Net Sales Up 15% YOY, Strong Growth in Key Brands
Swiss pharmaceutical giant Novartis (NYSE: NVS) released its Q1 2025 financial report, showing net sales...
Novartis Announces USD 23 Billion Investment to Expand U.S. Manufacturing and R&D Hubs
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced plans to invest USD 23 billion over...
Novartis’ Vanrafia Gets FDA Accelerated Approval for IgAN
Switzerland-based Novartis (NYSE: NVS) announced that it has received accelerated approval from the US Food...
Novartis’ Pluvicto Gains Expanded FDA Approval for Prostate Cancer Treatment
Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that it has received expanded indication approval from...
Novartis’ Fabhalta Approved by FDA for C3 Glomerulopathy Treatment
Swiss pharmaceutical giant Novartis’ (NYSE: NVS) iptacopan, marketed as Fabhalta, has received approval from the...
Novartis’ Cosentyx Approved by NMPA for Moderate to Severe Hidradenitis Suppurativa
Swiss giant Novartis’ (NYSE: NVS) Cosentyx (secukinumab) has secured another indication approval from China’s National...
Legend Biotech Reports Strong Q4 and Full Year 2024 Financial Results
China-based Legend Biotech Corporation (NASDAQ: LEGN) released its Q4 and full-year 2024 financial results, highlighting...
Kyorin Pharmaceutical Licenses KRP-M223 to Novartis for Global Development
Japan-based Kyorin Pharmaceutical Co., Ltd. announced a licensing agreement with Novartis (NYSE: NVS), granting the...
Hengrui’s Vunakizumab Receives NMPA Approval for nr-axSpA Treatment
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received another clinical trial...
Novartis to Acquire Anthos Therapeutics for $3.1B, Boosting Factor XI Inhibitor Portfolio
Swiss pharma giant Novartis (NYSE: NVS) announced plans to acquire Anthos Therapeutics, Inc., a cardiometabolic-focused...
CSPC Pharmaceutical’s Omalizumab Biosimilar Wins NMPA Approval for Allergic Asthma
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has received an additional indication approval from the...
Bio-Thera’s Biosimilars BAT2306 and BAT2506 Accepted for Review by NMPA and EMA
China-based Bio-Thera Solutions Inc. (SHA: 688177) announced that the market filings for its biosimilars BAT2306...
Novartis Reports 12% YOY Growth in Full-Year Net Sales
Swiss pharmaceutical major Novartis (NYSE: NVS) has released its Q4 and full-year 2024 financial report,...
Chongqing Genrix’s Xeligekimab Approved for Ankylosing Spondylitis by NMPA
China-based Chongqing Genrix Bio Pharmaceutical Co., Ltd (SHA: 688443) has announced receiving approval from the...
Novartis to Defend Entresto Patent After CAFC Ruling
Novartis (NYSE: NVS) has revealed a favorable decision by the US Court of Appeals for...
Light Horse Therapeutics Partners with Novartis in First-in-Class Drug Development
US-based Light Horse Therapeutics Inc., a small molecule drug developer that recently emerged from the...